Nurix Therapeutics $150 million at-the-market offering
Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Nurix Therapeutics, Inc. of its shares of common stock for up to an aggregate amount of $150 million. The common stock is listed on the Nasdaq Global Market under the symbol “NRIX.”
Based in San Francisco, California, Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders.
The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Jonathan Bye and Sherry Tan. The intellectual property and technology transactions team included partner David R. Bauer and associate Marisa Elena Bannon. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.